Cyclin D1 in various cancers: Mechanisms and clinical implications

Gastrointestinal cancers, including esophageal, gastric, hepatic, pancreatic, and colorectal malignancies, present a significant global health challenge. Their distinct characteristics characterized by abnormal cell proliferation, invasive behavior, and tumor formation make them highly aggressive and detrimental to human health. These diseases often lead to malnutrition, organ failure, and obstruction. Cyclin D1 protein is a critical regulator of cell cycle progression and an essential marker for comprehending the complex landscape of cancer biology. This research provides an in-depth exploration of gastrointestinal cancers by shedding light on their adverse effects on the human body while emphasizing the critical role played by cyclin D1 within this challenging disease context. Extensively studied in colorectal cancer as well as esophageal squamous cell carcinoma (ESCC), gastric cancer, and pancreatic cancer contexts. Cyclin D1 emerges as a key player. Specifically, in cases of colorectal cancer, overexpression of cyclin D1 is frequently linked to aggressive tumor behavior brought on by APC gene mutations and abnormal Wnt signalling pathway activation. Esophageal cancer patients especially those with ESCC frequently exhibit elevated levels of Cyclin D1 indicating poor prognosis. A similar trend is observed in gastric cancer where increased expression of cyclin D1 is linked to disease severity.